Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has been diagnosed with type 2 diabetes mellitus~* Has a hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at study start~* Has a body mass index (BMI)of 25 kg/m2 to 45 kg/m2, inclusive, at study start~* Has been on a stable treatment regimen of metformin for a minimum of 2 months prior to study start~* Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start:~  1. Hormone replacement therapy (female subjects)~ 2. Oral contraceptives (female subjects)~ 3. Antihypertensive agents~ 4. Lipid-lowering agents~ 5. Thyroid replacement therapy~ 6. Antidepressant agents~ 7. Drugs known to affect body weight, including prescription medications (e.g. orlistat \[XENICAL®\], sibutramine \[MERIDIA®\], topiramate \[TOPAMAX®\]) and over-the-counter antiobesity agents~Exclusion Criteria:~* Has been previously exposed to exenatide once weekly~* Has donated blood within 60 days of study start or is planning to donate blood during the study~* Currently being treated, or is expected to require or undergo treatment with any of the following treatment-excluded medications:~  1. Exenatide (BYETTA®) or any Dipeptidyl peptidase-4 DPP-4)inhibitor, sulfonylurea (SU), thiazolidinedione (TZD), or glucagon-like peptide (GLP)-1 analog within 3 months prior to study start~ 2. Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of study start~ 3. Insulin within 2 weeks of study start or for more than 1 week within 3 months of study start~ 4. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption~ 5. Drugs interacting with the CYP2C8 enzyme system, including gemfibrozil (LOPID®) and rifampin~* Has received any investigational drug within 1 month (or five half-lives of investigational drug, whichever is greater) of study start~* Has previously experienced a clinically significant adverse event (e.g., significant edema) related to TZD or DPP-4 inhibitor use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).